Clinical Aspects of the Use of Botulinum Toxin Type A in the Treatment of Dysfunction of the Masticatory System

Adv Clin Exp Med. 2016 May-Jun;25(3):569-73. doi: 10.17219/acem/41923.

Abstract

The purpose of this work is to present a new, still experimental method of treating temporomandibular disorders (TMD) by injecting botulinum toxin Type A (TBX-A), using its effects not as a toxin but as a medication. The mechanism of TBX-A, indications and contraindications for its use, as well as possible side effects, are discussed. Temporomandibular disorders are of concern to approximately 70-80% of the population. The effect of botulinum toxin depends on blocking the release of acetylcholine from a presynaptic neuromuscular synapse and, in the autonomous system, blocking its release from post-ganglionic cholinergic neurons. In cases of long-term TMJ disorders, muscle activity increases and spastic contractions may even appear. TBX-A offers an opportunity for a normal social and family life for many patients suffering from masticatory system disorders (MSD), who have been isolated from the environment by pain. The study is based on a review of the literature and the authors' own experiences during several attempts to treat patients by this method. TBX-A is a safe medicine when the injection is performed by a well-trained physician.

Keywords: botulinum toxin type A; dysfunction of the masticatory system; stomatognathic system.

Publication types

  • Review

MeSH terms

  • Botulinum Toxins, Type A / administration & dosage
  • Botulinum Toxins, Type A / therapeutic use*
  • Humans
  • Injections, Intramuscular
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / innervation
  • Muscle, Skeletal / physiopathology
  • Neuromuscular Agents / administration & dosage
  • Neuromuscular Agents / therapeutic use
  • Pain / physiopathology
  • Pain / prevention & control*
  • Stomatognathic System / drug effects*
  • Stomatognathic System / physiopathology
  • Temporomandibular Joint Disorders / drug therapy*
  • Temporomandibular Joint Disorders / physiopathology
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A